Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$6.26 -0.2%	$6.21	$3.93 ▼ $7.32	$320.75M	1.55	636,456 shs	414,463 shs
ARCT Arcturus Therapeutics	$11.91 -0.6%	$13.15	$8.04 ▼ $25.88	$324.90M	2.26	359,176 shs	396,324 shs
ELUT Elutia	$2.01 +1.5%	$1.98	$1.61 ▼ $5.12	$81.41M	0.88	22,131 shs	4,240 shs
NBTX Nanobiotix	$7.38 +2.6%	$5.30	$2.76 ▼ $7.74	$338.89M	0.45	7,672 shs	6,741 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	-1.88%	-1.57%	+7.36%	+18.98%	+41.86%
ARCT Arcturus Therapeutics	-1.88%	-1.88%	-13.19%	+9.11%	-36.04%
ELUT Elutia	+0.51%	-2.46%	-12.78%	-4.81%	-30.28%
NBTX Nanobiotix	+4.81%	+4.20%	+32.41%	+110.85%	+53.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABEO Abeona Therapeutics	3.8624 of 5 stars	3.5	1.0	4.5	2.9	2.5	0.0
ARCT Arcturus Therapeutics	2.7482 of 5 stars	3.6	2.0	0.0	2.6	2.5	0.6
ELUT Elutia	3.0515 of 5 stars	3.5	5.0	0.0	0.0	3.3	0.6
NBTX Nanobiotix	0.3318 of 5 stars	1.3	3.0	0.0	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	3.00	Buy	$19.25	207.51% Upside
ARCT Arcturus Therapeutics	3.11	Buy	$54.00	353.40% Upside
ELUT Elutia	3.00	Buy	$8.00	298.01% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	8.40% Upside

Current Analyst Ratings Breakdown

Latest ELUT, ARCT, ABEO, and NBTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
6/2/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$19.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/16/2025	ABEO Abeona Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $20.00
5/15/2025	ABEO Abeona Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00
5/9/2025	ELUT Elutia	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00

(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$3.50M	91.50	N/A	N/A	$1.01 per share	6.20
ARCT Arcturus Therapeutics	$152.31M	2.12	N/A	N/A	$8.90 per share	1.34
ELUT Elutia	$24.38M	3.39	N/A	N/A	($1.31) per share	-1.53
NBTX Nanobiotix	$39.18M	8.88	N/A	N/A	($1.51) per share	-4.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	-$63.73M	-$1.27	N/A	N/A	N/A	N/A	-118.82%	-52.48%	8/11/2025 (Estimated)
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	0.00	N/A	N/A	-47.47%	-27.41%	-19.01%	8/11/2025 (Estimated)
ELUT Elutia	-$53.95M	-$1.93	0.00	N/A	N/A	-168.23%	N/A	-96.70%	8/14/2025 (Estimated)
NBTX Nanobiotix	-$73.73M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)

Latest ELUT, ARCT, ABEO, and NBTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	ABEO Abeona Therapeutics	-$0.39	N/A	N/A	N/A	$21.71 million	N/A
8/11/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	N/A	N/A	N/A	$17.64 million	N/A
5/15/2025	Q1 2025	ABEO Abeona Therapeutics	-$0.35	-$0.24	+$0.11	-$0.24	N/A	N/A
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/8/2025	Q1 2025	ELUT Elutia	-$0.20	-$0.21	-$0.01	-$0.21	$6.65 million	$6.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
ELUT Elutia	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.27	4.90	4.90
ARCT Arcturus Therapeutics	0.06	5.64	5.64
ELUT Elutia	N/A	0.81	0.70
NBTX Nanobiotix	N/A	1.04	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
ARCT Arcturus Therapeutics	94.54%
ELUT Elutia	74.03%
NBTX Nanobiotix	38.81%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	6.90%
ARCT Arcturus Therapeutics	16.60%
ELUT Elutia	27.60%
NBTX Nanobiotix	3.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	51.16 million	47.63 million	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.62 million	Optionable
ELUT Elutia	180	41.12 million	29.77 million	Not Optionable
NBTX Nanobiotix	100	47.13 million	45.51 million	Not Optionable

ELUT, ARCT, ABEO, and NBTX Headlines

Recent News About These Companies

Nanobiotix (NASDAQ:NBTX) Stock Price Up 2.9% - Should You Buy?

July 30, 2025 | marketbeat.com

Guggenheim Reaffirms Their Buy Rating on Nanobiotix (NBTX)

July 25, 2025 | theglobeandmail.com

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3) - Morningstar

July 8, 2025 | morningstar.comM

Nanobiotix (NASDAQ:NBTX) Stock Price Down 2.5% - Should You Sell?

July 8, 2025 | marketbeat.com

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)

July 7, 2025 | globenewswire.com

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference

May 28, 2025 | globenewswire.com

Nanobiotix Provides First Quarter 2025 Operational and Financial Update

May 21, 2025 | globenewswire.com

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

May 12, 2025 | globenewswire.com

Nanobiotix Reveals Favorable Results Of JNJ-1900 Study Pancreatic Cancer; Seeks Further Evaluation

May 5, 2025 | finanznachrichten.de

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

May 5, 2025 | globenewswire.com

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

April 30, 2025 | globenewswire.com

Nanobiotix price target lowered to $8 from $12 at Guggenheim

April 5, 2025 | markets.businessinsider.com

Nanobiotix (NBTX) Gets a Hold from UBS

April 5, 2025 | markets.businessinsider.com

Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript

April 3, 2025 | seekingalpha.com

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

April 2, 2025 | globenewswire.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Nanobiotix (NBTX) and PTC Therapeutics (PTCT)

April 2, 2025 | theglobeandmail.com

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

March 31, 2025 | globenewswire.com

Nanobiotix reports promising NSCLC treatment study results

March 29, 2025 | investing.com

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

March 27, 2025 | globenewswire.com

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3)

March 21, 2025 | djournal.comD

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

March 20, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELUT, ARCT, ABEO, and NBTX Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$6.26 -0.01 (-0.16%)

Closing price 04:00 PM Eastern

Extended Trading

$6.35 +0.09 (+1.45%)

As of 06:15 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Arcturus Therapeutics NASDAQ:ARCT

$11.91 -0.07 (-0.58%)

Closing price 04:00 PM Eastern

Extended Trading

$11.95 +0.04 (+0.34%)

As of 06:59 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Elutia NASDAQ:ELUT

$2.00 +0.02 (+1.01%)

As of 04:00 PM Eastern

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Nanobiotix NASDAQ:NBTX

$7.40 +0.21 (+2.85%)

As of 03:59 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time